Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenues:
License revenue, net	$ 0	$ 0	$ 0	$ 2,125,000
Laboratory revenues, net	293,421	289,898	972,121	419,825
Total Revenues	293,421	289,898	972,121	2,544,825
Operating Costs and Expenses:
General and administrative	681,805	601,806	2,649,623	2,000,262
Research and development	288,964	229,044	800,923	962,766
Costs of laboratory services	260,881	192,176	805,881	430,001
Total Operating Costs and Expenses	1,231,650	1,023,026	4,256,427	3,393,029
Loss from Operations	(938,229)	(733,128)	(3,284,306)	(848,204)
Other Income (Expense):
Warrant expense	0	0	(1,491,996)	0
Change in fair value of warrant liability	(164,993)	0	(242,464)	0
Interest income	6,868	0	6,868
Other income (expense)	(1,625)	293	47,562	7,629
Total Other Income (Expense), net	(159,750)	293	(1,680,030)	7,629
Net Income (Loss)	(1,097,979)	(732,835)	(4,964,336)	(840,575)
Net Income (Loss) Per Share - Basic and Dilutive (in dollars per share)	$ (0.04)	$ (0.03)	$ (0.18)	$ (0.04)
Weighted average number of common shares outstanding during the period - Basic and Dilutive (in shares)	$ 28,089,492	$ 23,003,033	$ 27,075,730	$ 22,095,349